What are your top takeaways from ATS 2023?

1. The potential role of biologics in COPD
2. The importance of mucus in bronchitic type
3. Potential addition of Ensifentrine to COPD therapeutic options

After over ten years with no drug of a new class approved for COPD, there’s at least some hope for progress.

Three standouts to me (as an ILD and acute lung injury doc/researcher...I'm biased to these sorts of talks):

Tuesday, Clinical and Translational Studies in Mechanical Ventilation: RAPiD session, included studies investigating patient-vent interactions, treatment for septic shock, bioinformatics, and ...